Synovus Financial Corp lifted its stake in shares of CryoLife, Inc. (NYSE:CRY) by 21.4% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 12,394 shares of the medical equipment provider’s stock after buying an additional 2,185 shares during the period. Synovus Financial Corp’s holdings in CryoLife were worth $248,000 as of its most recent SEC filing.
Other large investors also recently made changes to their positions in the company. William Blair Investment Management LLC acquired a new stake in CryoLife in the second quarter valued at $4,517,000. Elk Creek Partners LLC boosted its position in CryoLife by 70.8% during the first quarter. Elk Creek Partners LLC now owns 496,917 shares of the medical equipment provider’s stock valued at $8,274,000 after acquiring an additional 205,971 shares during the last quarter. Dialectic Capital Management LP bought a new stake in CryoLife during the first quarter valued at $2,238,000. Dimensional Fund Advisors LP boosted its position in CryoLife by 5.7% during the first quarter. Dimensional Fund Advisors LP now owns 1,849,248 shares of the medical equipment provider’s stock valued at $30,790,000 after acquiring an additional 100,125 shares during the last quarter. Finally, Royce & Associates LP boosted its position in CryoLife by 32.5% during the first quarter. Royce & Associates LP now owns 395,700 shares of the medical equipment provider’s stock valued at $6,588,000 after acquiring an additional 97,000 shares during the last quarter. Institutional investors own 68.85% of the company’s stock.
Shares of CryoLife, Inc. (NYSE:CRY) opened at 21.75 on Friday. The company has a market cap of $727.45 million, a PE ratio of 65.91 and a beta of 0.97. CryoLife, Inc. has a 12 month low of $14.03 and a 12 month high of $22.85. The firm’s 50-day moving average is $19.45 and its 200-day moving average is $18.16.
CryoLife (NYSE:CRY) last released its quarterly earnings data on Monday, July 24th. The medical equipment provider reported $0.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.10 by $0.02. CryoLife had a net margin of 6.16% and a return on equity of 7.41%. The firm had revenue of $47.80 million for the quarter, compared to analysts’ expectations of $47.02 million. During the same quarter in the previous year, the company earned $0.13 earnings per share. The company’s revenue for the quarter was up 1.5% compared to the same quarter last year. On average, equities research analysts predict that CryoLife, Inc. will post $0.43 earnings per share for the current year.
A number of brokerages have commented on CRY. BidaskClub cut shares of CryoLife from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st. Zacks Investment Research raised shares of CryoLife from a “hold” rating to a “buy” rating and set a $21.00 price target on the stock in a research report on Thursday, June 8th. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $22.00.
In other CryoLife news, VP Amy Horton sold 9,577 shares of the business’s stock in a transaction dated Tuesday, June 27th. The shares were sold at an average price of $20.00, for a total value of $191,540.00. Following the transaction, the vice president now owns 112,282 shares in the company, valued at $2,245,640. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO James P. Mackin sold 43,050 shares of the business’s stock in a transaction dated Tuesday, September 5th. The shares were sold at an average price of $22.09, for a total transaction of $950,974.50. Following the completion of the transaction, the chief executive officer now owns 398,399 shares in the company, valued at approximately $8,800,633.91. The disclosure for this sale can be found here. Insiders sold 178,627 shares of company stock worth $3,915,765 in the last 90 days. Corporate insiders own 6.00% of the company’s stock.
CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.
Want to see what other hedge funds are holding CRY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CryoLife, Inc. (NYSE:CRY).
Receive News & Ratings for CryoLife Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoLife Inc. and related companies with MarketBeat.com's FREE daily email newsletter.